Patients receiving SGLT2 inhibitors were more likely to have high levels of hyperlipidemia and obesity and to be simultaneously receiving GLP-1 agonists, insulin, metformin, and statins compared with those receiving DPP4 inhibitors. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.